Malaria, Vivax: Clinical Trials

22 trials for Malaria, Vivax, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 4 recruiting, 2 not yet recruiting, 1 terminated. 22 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 322Completed 14, Recruiting 4, Not yet recruiting 2, Terminated 1, Withdrawn 1
Phase 24Not yet recruiting 2, Completed 1, Withdrawn 1

Follow Malaria, Vivax: new trials by email Literature Review of Malaria, Vivax trials Research Report on Malaria, Vivax

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Postpartum 8-aminoquinoline Breast Milk Study
Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers
Phase 2 / Phase 3Not yet recruitingCurtin University602026-04-012026-03-18
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
PvSeroTAT, Control - Malaria Vivax, Malaria Falciparum
Phase 3RecruitingLondon School of Hygiene and Tropical Medicine192002025-05-122026-09-18
An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
Tafenoquine, Primaquine, Chloroquine - Malaria, Vivax
Phase 3RecruitingGlaxoSmithKline3242024-11-132026-10-01
FocaL Mass Drug Administration for Vivax Malaria Elimination
Focal Mass Drug Administration (fMDA) - Plasmodium Vivax Malaria, Malaria
Phase 3RecruitingUniversity of California, San Francisco75302024-10-142026-06-09
Plasmodium Immunotherapy for Advanced Ovarian Cancer
Plasmodium immunotherapy - Advanced Ovarian Cancer
Phase 2 / Phase 3Not yet recruitingCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.302024-07-202024-07-22
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Tafenoquine, Primaquine - Vivax Malaria
Phase 3RecruitingMenzies School of Health Research10902024-05-102025-07-18
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Primaquine double dose over 14 days, Primaquine single dose over 14 days - Malaria, Vivax, Relapse
Phase 2 / Phase 3WithdrawnUniversity of California, San Francisco2023-01-202023-05-11
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
Tafenoquine, Primaquine - Vivax Malaria, Plasmodium Vivax
Phase 3CompletedMenzies School of Health Research9602021-04-252024-10-08
DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil
CQ coadministered with PQ, DHA-PQP coadministered with PQ, CQ and PQ starting on Day 42 - Malaria, Vivax, Therapeutics
Phase 3CompletedFundação de Medicina Tropical Dr. Heitor Vieira Dourado4192018-07-052023-06-12
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Tafenoquine, Matched-Placebo for Tafenoquine, Primaquine - Malaria, Vivax
Phase 3CompletedGlaxoSmithKline1502018-04-082020-07-24
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
Tafenoquine, Tafenoquine Placebo, Chloroquine - Malaria, Vivax
Phase 3CompletedGlaxoSmithKline2512015-04-302018-05-16
Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection
Chloroquine, Primaquine - Malaria, Vivax
Phase 2 / Phase 3CompletedOswaldo Cruz Foundation2042014-08-012016-02-25
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
Dihydroartemisinin-Piperaquine, Chloroquine - Vivax Malaria
Phase 3CompletedUniversity of Oxford6802012-02-012016-04-28
Artemether/Lumefantrine and Vivax Malaria
tablets artemether/lumefantrine - Vivax Malaria
Phase 3CompletedUniversity of Khartoum382011-09-012013-01-17
Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria
Dihydroartemisinin/piperaquine + primaquine, Artesunate-amodiaquine + primaquine - Vivax Malaria
Phase 3CompletedUniversity of Oxford3312011-01-012013-08-29
Study on the Treatment of Vivax Malaria
Artesunate, Chloroquine, Chloroquine/Primaquine - Vivax Malaria
Phase 3CompletedUniversity of Oxford6552010-05-012013-08-28
Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea
chloroquine, sulphadoxine pyrimethamine, LLIN, azithromycin, sulphadoxine pyrimethamine, LLIN - Malaria in Pregnancy, Sexually Transmitted Infections
Phase 3CompletedUniversity of Melbourne27932009-11-012013-04-23
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
Pyronaridine - artesunate, Chloroquine - Malaria
Phase 3TerminatedMedicines for Malaria Venture302007-09-062022-01-26
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Dihydroartemisinin + Piperaquine (Artekin), artesunate-sulphadoxin/pyrimethamine, chloroquine - Uncomplicated Falciparum Malaria, Vivax Malaria
Phase 3CompletedUniversity of Oxford10862007-07-012018-05-09
Eight Week Primaquine Regimen for the Treatment of Vivax Malaria
primaquine - Malaria, Vivax Malaria
Phase 3CompletedLondon School of Hygiene and Tropical Medicine1502004-04-012017-01-12

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Malaria (7)  ·  Malaria, Falciparum (4)  ·  Recurrence (3)  ·  Anemia (1)  ·  Breast Feeding (1)  ·  Hemolysis (1)  ·  Parasitic Diseases (1)  ·  Sexually Transmitted Diseases (1)  ·  Treponemal Infections (1)

Broader conditions

Infections (22)  ·  Mosquito-Borne Diseases (22)  ·  Protozoan Infections (22)  ·  Vector Borne Diseases (22)  ·  Parasitic Diseases (21)  ·  Malaria (15)  ·  Disease Attributes (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Bacterial Infections (1)  ·  Bacterial Infections and Mycoses (1)  ·  Behavior (1)  ·  Communicable Diseases (1)  ·  Feeding Behavior (1)  ·  Genital Diseases (1)

Interventions

Primaquine (12)  ·  Chloroquine (9)  ·  tafenoquine (6)  ·  Artesunate (2)  ·  artenimol (2)  ·  fanasil, pyrimethamine drug combination (2)  ·  piperaquine (2)  ·  Amodiaquine (1)  ·  Artemether (1)  ·  Azithromycin (1)  ·  Food (1)  ·  Lumefantrine (1)  ·  Pyrimethamine (1)  ·  Water (1)  ·  amodiaquine, artesunate drug combination (1)

Sponsors

London School of Hygiene and Tropical Medicine (4)  ·  University of Oxford (4)  ·  GlaxoSmithKline (3)  ·  Menzies School of Health Research (2)  ·  University of California, San Francisco (2)  ·  CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. (1)  ·  Curtin University (1)  ·  Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (1)  ·  Medicines for Malaria Venture (1)  ·  Oswaldo Cruz Foundation (1)  ·  University of Khartoum (1)  ·  University of Melbourne (1)

Countries

Brazil (4)  ·  Ethiopia (4)  ·  Indonesia (4)  ·  Pakistan (3)  ·  Papua New Guinea (3)  ·  Thailand (3)  ·  Peru (2)  ·  Afghanistan (1)  ·  Cambodia (1)  ·  China (1)  ·  Colombia (1)  ·  India (1)  ·  Madagascar (1)  ·  South Korea (1)  ·  Sudan (1)

Top investigators

Francois Nosten, MD (2)  ·  Mark Rowland, PhD (2)  ·  Alejandro Llanos-Cuentas, MD, PhD (1)  ·  Ayodhia Pitaloka Pasaribu, MD (1)  ·  Brioni Moore, PhD (1)  ·  Chris Drakeley (1)  ·  Christopher Whitty, FRCP (1)  ·  Cindy Chu, MD (1)  ·  Fitsum G Tadesse (1)  ·  Ghulam R Awab, MD (1)  ·  Guo Shuiqun, Ph.D., M.D. (1)  ·  Kamala N Thriemer, PhD (1)  ·  Kamala Thriemer, MD, MPH, PhD (1)  ·  Kate Graham, MSc (1)

Results publications

PMID 36534705, PMID 17519409, PMID 18682739, PMID 20409302, PMID 22427705, PMID 23217037, PMID 23926329, PMID 25591391, PMID 26006260, PMID 26286026, PMID 26917051, PMID 28103875, PMID 28170391, PMID 29889239, PMID 30650326, PMID 30782991, PMID 30952158, PMID 34181872, PMID 34398667, PMID 34607575, PMID 35619134, PMID 37236221, PMID 40321759, PMID 41088393, PMID 41690325, PMID 42114535, PMID 42575554

NIH funding

U01AI157962 (1)